Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 16, 2024 1:16pm
196 Views
Post# 36043761

RE:RE:RE:New Press Release - Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

RE:RE:RE:New Press Release - Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Easy spin. Shorting as predicted. 

The cGAr news is great. People want to see instant partnership etc
knowig the inclusion of a modified panc trial that could lead to direct approval is a great negotiation piece. 

The FDA mbc results very soon. Leading to green light for phase 3.
incluing China partner & milestone payments 
so, you can moan & groan about the low SP
an opportunity? 

sell, hold or buy? 

alwsys the same options 
or yes almost forgot, shorting 
again, please do. I'm looking forward tjj on a nice short squeeze 

<< Previous
Bullboard Posts
Next >>